Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Luvometinib - Shanghai Fosun Pharmaceutical

Next Previous
Drug Profile

Luvometinib - Shanghai Fosun Pharmaceutical

Alternative Names: FCN-159

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Fochon Pharmaceutical
  • Developer Shanghai Fosun Pharmaceutical
  • Class Aminopyridines; Aniline compounds; Antineoplastics; Benzene derivatives; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridazines; Small molecules; Sulfonamides; Vascular disorder therapies
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Arteriovenous malformations; Langerhans cell histiocytosis; Malignant histiocytic disorders; Plexiform neurofibroma
  • Phase II Glioma
  • No development reported Malignant melanoma

Most Recent Events

  • 04 Jun 2025 Shanghai Fosun Pharmaceutical plans a phase III trial for Glioma in China (PO) in June 2025 (NCT07004075)
  • 02 Jun 2025 Shanghai Fosun Pharmaceutical plans a phase I/II trial Neurofibromatosis-1 (In Children, In Adolescents, In Adults, Inoperable/unresectable, Second-line therapy or greater) in China (PO) (CTR20251956)
  • 02 Jun 2025 Shanghai Fosun Pharmaceutical plans a phase II trial Arteriovenous malformations (In Adolescents, In Adults, Inoperable/unresectable, Second-line therapy or greater) in China (PO) (CTR20244693)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top